Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma
- 1 January 1990
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 26 (8), 891-895
- https://doi.org/10.1016/0277-5379(90)90193-w
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Histological Classification of Canine Malignant LymphomasJournal of Veterinary Medicine Series A, 1988
- Reporting outcomes in Hodgkin's disease and lymphoma.Journal of Clinical Oncology, 1987
- Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.Journal of Clinical Oncology, 1987
- Fatal Pulmonary Embolism and Antithrombin III Deficiency in Adult Lymphoblastic Leukaemia during L-Asparaginase TherapyActa Haematologica, 1983
- National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usageCancer, 1982
- ANTITHROMBIN III DEFICIENCY DURING ASPARAGINASE THERAPYThe Lancet, 1980
- Immunological responses to l-asparaginaseJournal of Clinical Investigation, 1971
- Clinical pharmacologic studies of L‐asparaginaseClinical Pharmacology & Therapeutics, 1970
- L-Asparaginase in the Treatment of Neoplastic Diseases of the Dog, Cat and CowPublished by Springer Nature ,1970
- L-AsparaginaseNew England Journal of Medicine, 1969